Abiopharma

SEPTERNA, INC. (SEPN)

Symbol	SEPN
Name	SEPTERNA, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	250 EAST,GRAND AVENUE, SOUTH SAN FRANCISCO, California, 94080, United States
Telephone	650-338-3533
Fax	—
Email	—
Website	https://septerna.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001984086
Description	Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786. Additional info from NASDAQ: Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786.

2026-07-02 23:00

Long Daniel D. 🟡 adjusted position in 3.3K shares (1 derivative) of Septerna, Inc. (SEPN) at $34.81 Transaction Date: Jul 01, 2026 | Filing ID: 295106

2026-06-30 23:52

RA CAPITAL MANAGEMENT, L.P. 🟢 acquired 15.0K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 000718

2026-06-30 23:01

Shaikhly Samira 🟡 adjusted position in 2.2K shares (1 derivative) of Septerna, Inc. (SEPN) at $35.18 Transaction Date: Jun 29, 2026 | Filing ID: 291059

2026-06-30 23:00

Bassan Abraham 🟢 acquired 15.0K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 291056

2026-06-30 23:00

Sharp Shalini 🟢 acquired 15.0K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 291055

2026-06-30 23:00

Coulie Bernard 🟢 acquired 15.0K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 291054

2026-06-30 23:00

Tong Jeffrey K 🟢 acquired 15.0K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 291053

2026-06-30 23:00

Gottesdiener Keith Michael 🟢 acquired 11.3K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 291052

2026-06-30 23:00

Ezekowitz Alan 🟢 acquired 15.0K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 291050

2026-06-30 23:00

Simson Jake 🟢 acquired 15.0K shares (1 derivative) of Septerna, Inc. (SEPN) at $37.34 Transaction Date: Jun 26, 2026 | Filing ID: 291051

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07433179	A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Parti…	Phase1	Healthy Volunteers	Recruiting	2026-03-04	2027-02-01	ClinicalTrials.gov
NCT07069036	A Study to Evaluate Single and Multiple Doses of SEP-631 in Healthy Adult Volun…	Phase1	Healthy Volunteers	Completed	2025-07-15	2025-12-18	ClinicalTrials.gov

Total clinical trials: 2

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036

Total products: 32